supported by the National Natural Science Foundation of China(81872986);the"Double First-Class"University project(CPU2018GF03,China);the 111 Project from the Ministry of Education of China;the State Administration of Foreign Export Affairs of China(B18056);the Drug Innovation Major Project(2018ZX09711-001-007,2018ZX09735002-003,China)。
Although multifarious tumor-targeting modifications of nanoparticulate systems have been attempted in joint efforts by our predecessors,it remains challenging for nanomedicine to traverse physiological barriers involv...
supported by the National Cancer Institute of the National Institutes of Health under Award Number 1R01CA234115;supported by NIH RR0631401;RR12948;NSF CHE-9115282;DBI-9604689;the Murdock Charitable Trust;private donors Don and Marianna Matteson.
We have recently developed an enzyme-directed immunostimulant(EDI)prodrug motif,which is metabolized to active immunostimulant by cancer cells and,following drug efflux,activates nearby immune cells,resulting in immun...
Aim: To investigate whether R-848 (resiquimod, toll-like receptor 7/8 agonist) can induce late preconditioning in neonatal cardiac myocytes. Methods: The protective effects of R-848 on neonatal myocytes against an...